Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
2.450
-0.110 (-4.30%)
At close: Aug 13, 2025, 4:00 PM
2.510
+0.060 (2.45%)
Pre-market: Aug 14, 2025, 9:00 AM EDT
Soligenix Revenue
Soligenix had revenue of $2.34K in the twelve months ending March 31, 2025, down -99.67% year-over-year. In the year 2024, Soligenix had annual revenue of $119.37K, down -85.78%.
Revenue (ttm)
$2.34K
Revenue Growth
-99.67%
P/S Ratio
3,414.88
Revenue / Employee
$146
Employees
16
Market Cap
8.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SNGX News
- 6 days ago - NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer - GlobeNewsWire
- 14 days ago - Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease - PRNewsWire
- 5 weeks ago - Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones - PRNewsWire
- 6 weeks ago - Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions - PRNewsWire
- 2 months ago - Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials - GlobeNewsWire
- 3 months ago - Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - PRNewsWire
- 4 months ago - Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks - PRNewsWire
- 5 months ago - IBN Initiates Coverage of Soligenix Inc. - GlobeNewsWire